Evidence brief
CJC-1295: Research evidence and Canadian regulatory context
This profile summarizes selected early physiology studies and their limits. It does not provide a treatment, administration, dosing, sourcing, stacking, or product-quality recommendation.
Evidence maturity: limited early human physiology evidence; long-term clinical outcomes remain unestablished.
Human evidence
Two cited 2006 studies in specific healthy-adult research populations reported changes in growth-hormone and IGF-1 biomarkers during limited study periods. Those biomarker findings do not establish a clinical benefit, long-term safety, or an individual-use protocol.
Preclinical context
The cited work is useful for understanding a growth-hormone-releasing-hormone analogue and observed biomarker effects in controlled research settings. It should not be extrapolated to body composition, recovery, sleep, injury, or other health outcomes.
What remains unknown
The cited studies do not settle long-term outcomes, comparative clinical effectiveness, routine safety, indications, or any administration schedule for an individual.
Human-evidence table
A structured reading aid, not a treatment or product decision tool.
| Evidence maturity | Human-study context | Interpretation limit |
|---|---|---|
| limited early human physiology evidence; long-term clinical outcomes remain unestablished. | Two cited 2006 studies in specific healthy-adult research populations reported changes in growth-hormone and IGF-1 biomarkers during limited study periods. Those biomarker findings do not establish a clinical benefit, long-term safety, or an individual-use protocol. | The cited studies do not settle long-term outcomes, comparative clinical effectiveness, routine safety, indications, or any administration schedule for an individual. |
Canadian regulatory context
Health Canada’s public advisory describes general risks of unauthorized injectable peptide drugs. It does not turn short research-period biomarker observations into an authorized indication or personal-use protocol.
Evidence timeline
- 1
2006: controlled physiology studies report biomarker observations
- 2
Subsequent literature: no cited long-term clinical outcome base
- 3
Current: questions of indication, effectiveness, and long-term safety remain
How to read this evidence brief
Population first
Start with the studied population and protocol before interpreting an outcome. A result in a defined disease group does not automatically generalize to other readers.
Outcome second
Separate measured endpoints from broader claims about health, performance, product quality, or long-term benefit.
Limitations remain visible
The evidence gaps and regulatory context are part of the record, not footnotes to be ignored.
Sources and maintenance
Sources are linked directly so readers can review the original material and its limitations.
- Randomized placebo-controlled CJC-1295 study (2006)
Healthy-adult study of pharmacokinetics, biomarkers, and short study-period tolerability.
- GH pulsatility study (2006)
Healthy-men physiology study after a single CJC-1295 injection.
- Health Canada public advisory
Official Canadian information on unauthorized injectable peptide drugs.